G.ST Antivirals

G.ST Antivirals reports start of Phase 2 trial and announces appointment of Ronald Bruce Turner as new Chief Medical Officer

Phase 2 clinical trial started, first subject in on 2 April 2024 New CMO Ronald Bruce Turner MD, distinguished expert in the clinical research of rhinoviruses, to oversee trial and drive further clinical development. 9 April 2024 -- Vienna, Austria -- G.ST Antivirals, a clinical-stage biotechnology company applying innovative, host cell-based strategies to develop broad-spectrum...
Dr. Bohr-Gasse 7 (VBC6) 1030 Vienna Austria